よむ、つかう、まなぶ。
参考資料４_Action plan for whole genome analysis 2022 (36 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_38751.html |
| 出典情報 | 厚生科学審議会 科学技術部会全ゲノム解析等の推進に関する専門委員会（第20回 3／18）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
consideration. In addition, appropriate creation of
System B will be examined.
● FY2023 onward: System A will be maintained for medical institutions
carrying out specialist analysis, and System B will be
further expanded.
Rare/Intractable diseases
Uniform, high-quality information will be provided to patients through
centralized analysis and report preparation (System B). In addition, a
system will be established to provide appropriate explanations to patients
based on the characteristics of rare/intractable diseases and the results of
the Verification Project for Whole Genome Analysis of Rare/Intractable
Diseases (tentative name). For rare diseases with small numbers of
patients in particular, a joint international framework for collecting cases and
sharing data will be established to enable early diagnosis.
35
System B will be examined.
● FY2023 onward: System A will be maintained for medical institutions
carrying out specialist analysis, and System B will be
further expanded.
Rare/Intractable diseases
Uniform, high-quality information will be provided to patients through
centralized analysis and report preparation (System B). In addition, a
system will be established to provide appropriate explanations to patients
based on the characteristics of rare/intractable diseases and the results of
the Verification Project for Whole Genome Analysis of Rare/Intractable
Diseases (tentative name). For rare diseases with small numbers of
patients in particular, a joint international framework for collecting cases and
sharing data will be established to enable early diagnosis.
35